Streetbeat News

Equity Actions

GMAB

Genmab (NASDAQ:GMAB) has received diverse analyst ratings in the last three months, with 5 analysts offering views ranging from bullish to somewhat bearish. The average 12-month price target is $45.8, with a high of $50.00 and a low of $32.00, reflecting a 3.32% increase from the previous average of $44.33. Analyst Raghuram Selvaraju from HC Wainwright & Co. has adjusted his price target and maintained a 'Buy' rating, while Matthew Harrison from Morgan Stanley has lowered his rating to 'Underweight' with a price target of $32.00. Genmab, a biotech company specializing in antibody therapeutics, has shown a revenue growth rate of 16.08% and a high net margin of 44.88%, but its revenue growth lags behind industry peers. The company's financial health is strong, with an ROE of 7.11% and an ROA of 6.33%, and a low debt-to-equity ratio of 0.03.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 12:00 pm

CING

Cingulate has announced that Werth Family Investment Associates has converted $3.3 million of debt and accrued interest into equity at a conversion price of $4.785 per share. This conversion could indicate confidence in Cingulate's future prospects and may affect the company's financial structure and shareholder equity.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:56 am

SNX

TD SYNNEX Corporation (NYSE:SNX) announced a secondary public offering of 7.4 million shares held by affiliates of Apollo Global Management. The underwriters have an option to buy an additional 1.1 million shares. TD SYNNEX will not sell any shares nor receive proceeds from this offering. Concurrently, TD SYNNEX will repurchase up to $160 million of its common stock as part of its existing share repurchase program, using existing cash on hand.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:45 am

PBLA

Panbela Therapeutics has announced a public offering priced at $9 million. The offering includes 4.375 million common shares or pre-funded warrants, along with two classes of warrants to purchase up to 8.75 million shares at $2.06 per share and associated warrants.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:17 am

VERA

Vera Therapeutics, Inc., a biotech company focused on immunologic diseases, has announced a proposed public offering to sell $200 million of its Class A common stock. The company also plans to give underwriters a 30-day option to buy an additional 15% of the shares offered. The completion and terms of the offering are not guaranteed.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 11:16 am

BP

BP is facing pressure from activist investors to abandon its commitment to clean energy initiatives. These investors are pushing for a focus on more profitable oil and gas operations, challenging the company's strategy to transition towards more sustainable energy sources.

Portfolio Pulse from Charles Gross

January 29, 2024 | 9:40 am

FFIV

NRIM

NUE

SMCI

WHR

Investors are watching Super Micro Computer, Northrim BanCorp, Nucor Corporation, F5, Inc., and Whirlpool Corporation as they head into Monday with mixed U.S. stock futures. Super Micro Computer is expected to report earnings of $4.93 per share on $3.06 billion revenue, Northrim BanCorp authorized additional stock repurchase, Nucor is anticipated to earn $2.87 per share on $7.65 billion revenue, F5 is projected to report earnings of $3.04 per share on $685.34 million revenue, and Whirlpool is expected to post earnings of $3.56 per share on $4.98 billion revenue.

Portfolio Pulse from Avi Kapoor

January 29, 2024 | 9:12 am

HLNE

Hamilton Lane (NASDAQ:HLNE), a private markets investment management firm, has expanded its global Real Assets Investments Team by hiring Managing Director Dominik von Scheven in Frankfurt and Principal Taylor McManus in Canada. Both will focus on infrastructure investing and report to Brent Burnett. von Scheven, with over two decades of experience, will play a key role in European infrastructure equity investments and continue to grow the firm's Infrastructure Investments platform, which has increased by 35% to $57.6 billion in AUM over the last two years.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 8:12 am

AS

SUBL

Amer Sports, Inc (NYSE:AS) and BIOLINGUS (CAYMAN) LIMITED (NASDAQ:SUBL) are set to go public on Feb. 1, 2024, and Jan. 31, 2024, respectively. Amer Sports will offer 100 million shares at $17.00 each, while BIOLINGUS will offer 360,000 shares at $15.50 each. Both companies have a 180-day insider lock-up period post-IPO.

Portfolio Pulse from Benzinga Insights

January 28, 2024 | 5:03 pm

BRK-A

COST

Warren Buffett's Berkshire Hathaway Inc. sold its shares in Costco Wholesale Corporation in 2020, missing out on approximately $1.5 billion in gains as Costco's stock soared up to 127% since the sale. Berkshire Hathaway began investing in Costco in 1999, accumulating 4.3 million shares by mid-2020. Buffett has acknowledged the sale as a potential mistake during Berkshire's 2021 shareholder meeting.

Portfolio Pulse from Bibhu Pattnaik

January 27, 2024 | 9:20 pm